Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Does adjuvant ipilimumab have little adverse effect on quality of life?

Nature Reviews Clinical Oncology volume 14, pages 395–396 (2017)Cite this article

Subjects

Adjuvant ipilimumab is associated with an 11% improvement in 5-year overall survival in patients with high-risk melanoma, but at the cost of considerable toxicity, with half of patients discontinuing treatment owing to adverse events. An analysis of quality-of-life (QoL) outcomes, however, showed little impact of adverse effects of this treatment on QoL, which is puzzling.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  2. van Akkooi, A. C., Atkins, M. B., Agarwala, S. S. & Lorigan, P. Surgical management and adjuvant therapy for high-risk and metastatic melanoma. Am. Soc. Clin. Oncol. Educ. Book 35, e505–e514 (2016).

    Article  Google Scholar 

  3. Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).

    Article  CAS  Google Scholar 

  4. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).

    Article  Google Scholar 

  5. Coens, C. et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 18, 393–403 (2017).

    Article  CAS  Google Scholar 

  6. Howell, M., Lee, R., Bowyer, S., Fusi, A. & Lorigan, P. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer 88, 117–123 (2015).

    Article  Google Scholar 

  7. Agarwala, S. S. et al. Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J. Clin. Oncol. 35, 885–892 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paul Lorigan is at the University of Manchester and Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.,

    Paul Lorigan

  2. Adele C. Green is at the Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.,

    Adele C. Green

  3. at the QIMR Berghofer Medical Research Institute, Royal Brisbane and Woman's Hospital, 300 Herston Road, Herston, Queensland 4029, Australia.,

    Adele C. Green

Authors
  1. Paul Lorigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adele C. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Lorigan.

Ethics declarations

Competing interests

P.L. is a member of the European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group, where he chairs the Advanced Disease Subgroup. He had no involvement in EORTC 18071 trial, did not recruit patients to the trial, and was not privy to the results until they were published. P.L. has acted as a paid consultant/adviser to Amgen, BMS, GSK, MSD, Novartis, and Roche. He has received support for travel from BMS and MSD. A.G. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lorigan, P., Green, A. Does adjuvant ipilimumab have little adverse effect on quality of life?. Nat Rev Clin Oncol 14, 395–396 (2017). https://doi.org/10.1038/nrclinonc.2017.60

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.60

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research